The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress.
This study was to compare the impact of different biocompatible coated circuits on inflammatory response and oxidative stress induced during cardiopulmonary bypass (CPB). Seventy-eight patients undergoing elective coronary artery bypass grafting (CABG) with CPB were randomly assigned to five groups with different biocompatible coated circuits: Trillium, Bioline, Phosphorylcholine, Polymethoxyethyl acrylate (PMEA), and the uncoated control group. Blood was drawn at three different time points: before CPB, 6 and 72 hours post CPB. Unlike the Trillium group, serum levels of TNF-alpha in the Bioline and Phosphorylcholine groups significantly increased only at 72 hours post CPB (p < 0.05). Serum levels of IL-6 significantly increased at 6 and 72 hours post CPB in all groups (p < 0.01). The Trillium group showed a significant increase of IL-10 compared to the control group at 72 hours post CPB (p < 0.05). Serum levels of NOx in the Phosphorylcholine group significantly decreased at 6 hours post CPB compared to baseline (p < 0.05). Both the Bioline and Phosphorylcholine groups showed statistical decreases in serum NOx levels compared with other groups at 6 hours post CPB (p < 0.05). A significant difference in NOx levels between the Bioline and the control group was also observed at 72 hours post CPB. Myeloperoxidase levels were significantly elevated at 6 and 72 hours post CPB in all groups (p < 0.05). Inflammatory response and oxidative stress are elevated during CABG with CPB. Heparin-coated and the Phosphorylcholine-coated circuits induce less inflammatory responses and oxidative stress compared to other circuits.
Department of Pathology and Laboratory Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W8 Canada.
N
N
Sohn
J
J
Marcoux
T
T
Mycyk
J
J
Krahn
Qh
Q
Meng
D000368:Aged; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage*; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016753:Interleukin-10 / Q000819:agonists / Q000097:blood; D015850:Interleukin-6 / Q000819:agonists / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery*; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects*; D009195:Peroxidase / Q000097:blood / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000819:agonists / Q000097:blood
D020099:Coated Materials, Biocompatible; C508609:IL10 protein, human; C508600:IL6 protein, human; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D009569:Nitric Oxide; D009195:Peroxidase